ReviewClinical microbiology reviews2020
Remdesivir against COVID-19 and Other Viral Diseases.
Review in Clinical microbiology reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 3 syntheses or guidelines pooled it, 292 citations in OpenAlex.
- Exploring COVID-19 Pandemic Disparities with Transcriptomic Meta-analysis from the Perspective of Personalized Medicine.Journal of microbiology (Seoul, Korea) · 2024Pooled it
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.Drug design, development and therapy · 2022Pooled it
- Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021Pooled it
- Trial
- A versatile fluorescent reporter for Usutu virus drug screening and infection tracking.PNAS nexus · 2026Article
- Airway epithelia clear rhinovirus infection via two waves of cell extrusion.Science advances · 2026Article
- Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.Molecules (Basel, Switzerland) · 2026Article
- The transmembrane segments of SARS-CoV-2 nsp3 govern viral intracellular trafficking.Cell & bioscience · 2026Article
- Structural basis for RNA synthesis and inhibition of the orthobunyavirus polymerase.Nature communications · 2026Article
- A Box-Behnken design-assisted RP-HPLC method development and optimization for simultaneous determination of four antiviral drugs in pharmaceutical dosage forms.Scientific reports · 2026Article
- Enhanced Antiviral Activity of Novel Umifenovir Derivatives against SARS-CoV-2: Insights from an International Collaborative Study.ACS omega · 2026Article
- Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Treatment of non-effusive feline infectious peritonitis using oral remdesivir or GS-441524: a randomized, double-blind, non-inferiority trial.Journal of feline medicine and surgery · 2026Article
- A narrative review of SARS-CoV-2 variants and long COVID.Journal of thoracic disease · 2026Review
- Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants.JACS Au · 2026Article
- Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study.Scientific reports · 2025Article
- Synthetic host defense peptide inhibits SARS-CoV-2 replicationAntimicrobial agents and chemotherapy · 2025Article
- Deep learning in the discovery of antiviral peptides and peptidomimetics: databases and prediction tools.Molecular diversity · 2025Review
- Eco-Friendly Synchronous Spectrofluorimetric Method for Simultaneous Determination of Remdesivir and Acetyl Salicylic Acid in Spiked Human Plasma.Journal of fluorescence · 2025Article
- Eco-friendly spectrofluorimetric determination of remdesivir in the presence of its metabolite in human plasma for therapeutic monitoring in COVID-19 patients.Scientific reports · 2025Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic. Remdesivir (GS-5734) is the first approved treatment for severe coronavirus disease 2019 (COVID-19). It is a novel nucleoside analog with a broad antiviral activity spectrum among RNA viruses, including ebolavirus (EBOV) and the respiratory pathogens Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2. First described in 2016, the drug was derived from an antiviral library of small molecules intended to target emerging pathogenic RNA viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.